To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC)
administered by aerosolization in patients with non-small-cell lung cancer (any stage).
To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days
per week X 8 weeks, every 10 weeks.
To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A
specific protocol will be written for this part.